Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Hematologic Malignancy”

4,047 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 4,047 results

Testing effectiveness (Phase 2)WithdrawnNCT05170789
What this trial is testing

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Tulane University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Who this might be right for
Multiple Myeloma
Cephalon 62
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Looking for participantsNCT02203903
What this trial is testing

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Who this might be right for
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Catherine Bollard 50
Large-scale testing (Phase 3)Study completedNCT00546780
What this trial is testing

Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 31
Early research (Phase 1)Ended earlyNCT05712278
What this trial is testing

Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukaemia
Sanofi 7
Early research (Phase 1)WithdrawnNCT03605589
What this trial is testing

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Children's Hospital Medical Center, Cincinnati
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Very early researchLooking for participantsNCT07144020
What this trial is testing

Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Zhejiang University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05996185
What this trial is testing

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Who this might be right for
T Cell LymphomaT-cell Lymphoma
Yale University 22
Early research (Phase 1)Study completedNCT03441555
What this trial is testing

Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
AbbVie 36
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Not applicableNot Yet RecruitingNCT06472479
What this trial is testing

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University 66
Testing effectiveness (Phase 2)Study completedNCT02206425
What this trial is testing

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Testing effectiveness (Phase 2)Study completedNCT03436862
What this trial is testing

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Who this might be right for
Hodgkin Lymphoma
SCRI Development Innovations, LLC 37
Large-scale testing (Phase 3)Study completedNCT00657488
What this trial is testing

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 400
Early research (Phase 1)Active Not RecruitingNCT03479268
What this trial is testing

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+15 more
City of Hope Medical Center 18
Early research (Phase 1)UnknownNCT05457010
What this trial is testing

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Arcellx, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT00129168
What this trial is testing

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid
Kanisa Pharmaceuticals 100
Load More Results